Skip to content

Doxazosin Mesylate

FDA-approved product (tablet, oral), marketed as Cardura, Cardura Xl, Doxazosin Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Doxazosin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Hypertension
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxazosin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

    NCT01819220 · start 2009-04

    Registered record
    Registry ID
    NCT01819220
    Conditions
    Hypertension
    Interventions
    amlodipine/valsartan; hydrochlorothiazide/telmisartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2014-11
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionamlodipine/valsartan; hydrochlorothiazide/telmisartan
    PhasePhase 4
    Registry statusCompleted
  • Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

    NCT01386983 · start 2009-03

    Registered record
    Registry ID
    NCT01386983
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; 5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-06
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; 5ARI + AB
    PhaseNot recorded
    Registry statusCompleted
  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted
  • The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia

    NCT00687388 · start 2008-05

    Registered record
    Registry ID
    NCT00687388
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    selective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionselective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    PhasePhase 4
    Registry statusWithdrawn
  • Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

    NCT00713739 · start 2008-01

    Registered record
    Registry ID
    NCT00713739
    Conditions
    Kidney Stones
    Interventions
    Alfuzosin; nifedipine; doxazosin; prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-01
    Completion
    2012-12
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    InterventionAlfuzosin; nifedipine; doxazosin; prazosin
    PhasePhase 3
    Registry statusUnknown
  • Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS

    NCT00517179 · start 2006-04

    Registered record
    Registry ID
    NCT00517179
    Conditions
    Prostatic Hyperplasia; Impotence
    Interventions
    Vardenafil 10mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Impotence
    InterventionVardenafil 10mg
    PhaseNot applicable
    Registry statusCompleted
  • Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

    NCT02266537 · start 2005-11

    Registered record
    Registry ID
    NCT02266537
    Conditions
    Healthy
    Interventions
    Tamsulosin; Alfuzosin; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    Not recorded
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTamsulosin; Alfuzosin; Doxazosin; Placebo
    PhasePhase 1
    Registry statusCompleted
  • Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

    NCT00130156 · start 2005-10

    Registered record
    Registry ID
    NCT00130156
    Conditions
    High Blood Pressure
    Interventions
    Bunazosin; Doxazosin; Valsartin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    2009-03
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Blood Pressure
    InterventionBunazosin; Doxazosin; Valsartin
    PhasePhase 4
    Registry statusCompleted
  • Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

    NCT00563485 · start 2005-10

    Registered record
    Registry ID
    NCT00563485
    Conditions
    Prostatic Hyperplasia; Urinary Retention
    Interventions
    Doxazosin GITS (Cardura XL); Terazosin (Hytrin)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2006-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Urinary Retention
    InterventionDoxazosin GITS (Cardura XL); Terazosin (Hytrin)
    PhaseNot applicable
    Registry statusTerminated
  • Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy

    NCT00295555 · start 2004-01

    Registered record
    Registry ID
    NCT00295555
    Conditions
    Diabetes Mellitus; Essential Hypertension; Renal Failure
    Interventions
    Effects of doxazosin on morning surge in diabetic patients
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-04
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Essential Hypertension; Renal Failure
    InterventionEffects of doxazosin on morning surge in diabetic patients
    PhasePhase 4
    Registry statusCompleted
  • Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

    NCT00648323 · start 2003-11

    Registered record
    Registry ID
    NCT00648323
    Conditions
    Prostate
    Interventions
    Doxazosin mysylate GITS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate
    InterventionDoxazosin mysylate GITS
    PhasePhase 4
    Registry statusCompleted
  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted
  • Japan Morning Surge-1 Study

    NCT00285519 · start 2003-08

    Registered record
    Registry ID
    NCT00285519
    Conditions
    Hypertension
    Interventions
    Doxazosin (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-08
    Completion
    2005-08
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionDoxazosin (drug)
    PhasePhase 4
    Registry statusCompleted
  • Extracellular Fluid in Resistant Hypertension

    NCT00141596 · start 2003-07

    Registered record
    Registry ID
    NCT00141596
    Conditions
    Hypertension
    Interventions
    Cardura XL 4 mg bd; Amiloride 5 mg bd; Furosemide 40 mg bd
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2003-07
    Completion
    2006-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCardura XL 4 mg bd; Amiloride 5 mg bd; Furosemide 40 mg bd
    PhaseNot applicable
    Registry statusTerminated
  • Analyzing How Genetics May Affect Response to High Blood Pressure Medications

    NCT00563901 · start 2000-09

    Registered record
    Registry ID
    NCT00563901
    Conditions
    Hypertension; Coronary Disease; Cerebrovascular Accident
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-09
    Completion
    2004-05
    Enrolment
    37,939

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Coronary Disease; Cerebrovascular Accident
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted